Ron Shah1, Mikhail S Shchepinov2, Derek A Pratt1. 1. Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario, Canada K1N 6N5. 2. Retrotope Inc., Los Altos, California 94022, United States.
Abstract
Lipoxygenases (LOXs) have been implicated as central players in ferroptosis, a recently characterized cell death modality associated with the accumulation of lipid hydroperoxides: the products of LOX catalysis. To provide insight on their role, human embryonic kidney cells were transfected to overexpress each of the human isoforms associated with disease, 5-LOX, p12-LOX, and 15-LOX-1, which yielded stable cell lines that were demonstrably sensitized to ferroptosis. Interestingly, the cells could be rescued by less than half of a diverse collection of known LOX inhibitors. Furthermore, the cytoprotective compounds were similarly potent in each of the cell lines even though some were clearly isoform-selective LOX inhibitors. The cytoprotective compounds were subsequently demonstrated to be effective radical-trapping antioxidants, which protect lipids from autoxidation, the autocatalytic radical chain reaction that produces lipid hydroperoxides. From these data (and others reported herein), a picture emerges wherein LOX activity may contribute to the cellular pool of lipid hydroperoxides that initiate ferroptosis, but lipid autoxidation drives the cell death process.
Lipoxygenases (LOXs) have been implicated as central players in ferroptosis, a recently characterized cell death modality associated with the accumulation of lipid hydroperoxides: the products of LOX catalysis. To provide insight on their role, human embryonic kidney cells were transfected to overexpress each of the human isoforms associated with disease, 5-LOX, p12-LOX, and 15-LOX-1, which yielded stable cell lines that were demonstrably sensitized to ferroptosis. Interestingly, the cells could be rescued by less than half of a diverse collection of known LOX inhibitors. Furthermore, the cytoprotective compounds were similarly potent in each of the cell lines even though some were clearly isoform-selective LOX inhibitors. The cytoprotective compounds were subsequently demonstrated to be effective radical-trapping antioxidants, which protect lipids from autoxidation, the autocatalytic radical chain reaction that produces lipid hydroperoxides. From these data (and others reported herein), a picture emerges wherein LOX activity may contribute to the cellular pool of lipid hydroperoxides that initiate ferroptosis, but lipid autoxidation drives the cell death process.
Lipid peroxidation
has long been implicated in a staggering array
of human pathologies.[1] However, only recently
has a direct connection between lipid peroxidation and a specific
mode of cell death been recognized. Ferroptosis—coined for
this modality—was introduced in 2012.[2−7] It was initially ascribed to the caspase-independent cell death
resulting from glutathione depletion by the system x– inhibitor erastin.[8] Glutathione
depletion starves glutathione peroxidase 4 (Gpx4) of its reducing
cosubstrate, preventing the detoxification of (phospho)lipid hydroperoxides
(LOOH) by reduction to the corresponding (phospho)lipid alcohols (LOH).
Ferroptosis can also be induced by pharmacological inhibition of Gpx4
(e.g., with RSL3),[9] or via inducible deletion
of the gene encoding Gpx4.[10] Changes to
lipid metabolism that increase the pool of oxidizable polyunsaturated
(phospho)lipid or which disrupt iron homeostasis also sensitize cells
to ferroptosis.[11,12]The formation of cellular
LOOH is known to occur by two primary
mechanisms: an iron-catalyzed spontaneous peroxyl radical-mediated
chain reaction called autoxidation,[13] and
an enzyme-mediated process catalyzed by (non-heme) iron-dependent
lipoxygenases (LOXs) (Figure A).[14] Several reports have implicated
LOXs (the 15-LOX-1 isoform, in particular) as a key regulator in ferroptotic
cell death.[15,16] Evidence for the involvement
of LOX in ferroptosis is based largely on the observation that pharmacological
inhibition of LOX is cytoprotective.[15−17] Although it has also
been demonstrated that cells are resistant to ferroptosis when LOX
activity is knocked down using siRNAs,[16] only pharmacological inhibition of LOX has been shown to rescue gpx4–/– knockout mice;[10] disruption of the gene encoding 15-LOX-1 (alox15) failed to do so.[18]
Figure 1
(A) Formation
of cellular lipid hydroperoxides (LOOH) occurs primarily
by iron-accelerated free radical autoxidation and LOX-catalyzed oxidation
of polyunsaturated fatty acids. (B) Overexpression of 5-LOX, platelet
12-LOX, and 15-LOX-1 in HEK293 cells. (C) MS/MS transitions for the
5-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs) produced by
the overexpressed LOXs. HETEs were analyzed following reduction of
the corresponding hydroperoxyeicosatetraenoic acids (HPETEs) with
TCEP. (D) LC/MS/MS chromatograms of organic extracts of cell lysates
following incubation with 70 μM arachidonic acid for 10 min.
(E, F) RSL3- and erastin-induced ferroptosis in each cell line following
4 and 24 h incubation, respectively. Data represent the mean ±
SD of 3 independent experiments (P < 0.0001 and P ≤ 0.001 for LD50 values of RSL3 and
erastin as determined by one-way ANOVA followed by Dunnett’s
multiple comparisons test). (G) Flow cytograms of C11-BODIPY-treated
cells supplemented with 70 μM AA.
(A) Formation
of cellular lipid hydroperoxides (LOOH) occurs primarily
by iron-accelerated free radical autoxidation and LOX-catalyzed oxidation
of polyunsaturated fatty acids. (B) Overexpression of 5-LOX, platelet
12-LOX, and 15-LOX-1 in HEK293 cells. (C) MS/MS transitions for the
5-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs) produced by
the overexpressed LOXs. HETEs were analyzed following reduction of
the corresponding hydroperoxyeicosatetraenoic acids (HPETEs) with
TCEP. (D) LC/MS/MS chromatograms of organic extracts of cell lysates
following incubation with 70 μM arachidonic acid for 10 min.
(E, F) RSL3- and erastin-induced ferroptosis in each cell line following
4 and 24 h incubation, respectively. Data represent the mean ±
SD of 3 independent experiments (P < 0.0001 and P ≤ 0.001 for LD50 values of RSL3 and
erastin as determined by one-way ANOVA followed by Dunnett’s
multiple comparisons test). (G) Flow cytograms of C11-BODIPY-treated
cells supplemented with 70 μM AA.The identification of specific molecular and genetic inducers
of
ferroptosis enabled the Stockwell and Conrad groups to identify ferrostatin-1
(Fer-1)[19] and liproxstatin-1 (Lip-1)[17] as potent inhibitors of ferroptosis from high-throughput
screens—the former based on GSH depletion with erastin and
the latter by gpx4 knockout with Cre-recombinase.
The potencies of Lip-1 and Fer-1 compare very favorably to cytoprotection
afforded by known LOX inhibitors such as zileuton (5-LOX inhibitor),
PD146176 (15-LOX-1 inhibitor), and NDGA (a pan-LOX inhibitor). We
recently demonstrated that while Fer-1 and Lip-1 are poor inhibitors
of 15-LOX-1, they are excellent inhibitors of lipid peroxidation (autoxidation)
owing to their reactivity as radical-trapping antioxidants (RTAs),[20] compounds which reduce chain-carrying peroxyl
radicals.[21] In fact, both Fer-1 and Lip-1
are more effective RTAs in lipid bilayers than α-TOH, Nature’s
premier lipophilic RTA.[22] This observation
is fully consistent with their greater potency as inhibitors of ferroptosis
compared to α-TOH.[20] Moreover, highly
reactive designer RTAs, including lipophilic naphthyridinols and diarylamines,
are potent inhibitors of ferroptosis.[23,24] Thus, it follows
that either LOX inhibition or RTA activity can subvert ferroptosis,
suggesting that both LOX-catalyzed lipid oxygenation and lipid autoxidation
contribute to the execution of ferroptosis and preventing one or the
other can subvert it. Alternatively, the LOX inhibitors that have
been demonstrated to suppress ferroptosis may simply do so as RTAs.
Although it is known that zileuton, NDGA, and other redox-active LOX
inhibitors have “antioxidant” properties,[25] to the best of our knowledge, their reactivity
as RTAs have yet to be investigated.Given the confounding observations
surrounding the role of LOX
in the execution of ferroptosis (vide supra), we
have generated cells that have been stably transfected to overexpress
each of the three isoforms most commonly associated with disease (5-LOX,
platelet-type 12-LOX, and 15-LOX-1) and characterized both their sensitivity
to ferroptosis-inducing compounds and the ability of LOX inhibitors
and RTAs to rescue them from cell death. These data suggest that although
LOX activity may sensitize cells to ferroptosis by contributing to
the cellular pool of hydroperoxides, lipid autoxidation clearly drives
cell death.
Results
LOX Overexpression Sensitizes Cells to Ferroptosis
To provide insight on the potential role of different LOX isoforms
in the regulation of ferroptosis, LOX-overexpressing HEK293-derived
cell lines were generated by stable transfection with recombinant
pcDNA3/alox5, alox12, and alox15 constructs.[26] Overexpression
of each LOX was verified by immunoblotting (Figure B), and enzymatic activity was confirmed
by determination of the corresponding arachidonic acid oxygenation
products (hydroperoxyeicosatetraenoic acids, HPETEs) by UPLC/ESI-MS/MS
(Figure C,D). LOX
expression was not detected in the wild-type cells, and LOX overexpression
did not affect Gpx4 levels (Figure S1A–C).The sensitivity of the LOX-overexpressing cells to ferroptosis
was assessed by Gpx4 inhibition with (1S,3R)-RSL3[9] or GSH depletion with
erastin.[8] The transfected cell lines were
sensitized to ferroptosis induced by either agent, albeit to slightly
different extents (Figure E,F). LOX overexpression had a more dramatic effect on RSL3-induced
ferroptosis, dropping the LD50 from 6.8 μM in the
wild-type cells to 0.6, 0.4, and 0.5 μM in the 5-LOX-, p12-LOX-,
and 15-LOX-1-overexpressing cells, respectively. Erastin treatment
was characterized by LD50s of 6.6 μM in the wild-type
cells and 1.4, 0.9, and 1.7 μM in the 5-LOX-, p12-LOX-, and
15-LOX-1-overexpressing cells, respectively. A similar sensitization
of the LOX-overexpressing cells to the purported Gpx4 inhibitor ML210[27−29] was also observed (Figure S1D).Insight on the origin of the sensitization of the transfected cells
to ferroptosis is evident in the chromatograms shown in Figure D. Although LOX overexpression
results in an abundance of the specific regioisomeric H(P)ETE derived
from LOX catalyzed oxygenation of AA, the amount of nonspecific regioisomeric
H(P)ETEs also increase relative to the nontransfected cells. It should
be noted that several other regioisomers (i.e., 8-, and 11-H(P)ETE)
are also formed in these reactions (Figure S1E–G). Thus, the higher sensitivity of LOX-overexpressing cells to ferroptosis
may be ascribed to an initial increase in the concentration of specific
LOOH which can subsequently decompose to yield initiating species
(alkoxyl and/or hydroxyl radicals by the Fenton reaction) for nonenzymatic
lipid peroxidation (autoxidation). To corroborate that the LOX overproducing
cells experience a higher rate of (nonregiospecific) lipid autoxidiation
concomitant with the increase in regiospecific LOOH formation, C11-BODIPY was used to report on the formation of autoxidation
chain-carrying lipidperoxyl radicals.[30] Indeed, as is shown in Figure G, C11-BODIPY oxidation was significantly
higher in LOX-overexpressing cells compared to the nontransfected
cells, suggesting that, even in the presence of functional Gpx4, the
LOX-overexpressing cells undergo a higher rate of lipid peroxidation.
This difference was further exaggerated when Gpx4 was inhibited using
RSL3 (Figure S1H–K).
LOX-Overexpressing
Cells Are Rescued by Some LOX Inhibitors
and All Good RTAs
Given the foregoing results, we sought
to delineate the role of LOX-catalyzed lipid peroxidation and autoxidation
in ferroptosis by quantitating the potency of both LOX inhibitors
(Figures A–C, S2A–E) and RTAs (Figures D–F, S2F–J) in a systematic manner.
Figure 2
Structures of some LOX inhibitors (A), their
isoform-selectivity
(B), and potency as inhibitors of RSL3-induced ferroptosis in the
four different cell lines (C). Structures of common RTAs (D), their
activity as inhibitors of the various LOX isoforms (E), and potency
as inhibitors of RSL3-induced ferroptosis in the four different cell
lines (F).
Structures of some LOX inhibitors (A), their
isoform-selectivity
(B), and potency as inhibitors of RSL3-induced ferroptosis in the
four different cell lines (C). Structures of common RTAs (D), their
activity as inhibitors of the various LOX isoforms (E), and potency
as inhibitors of RSL3-induced ferroptosis in the four different cell
lines (F).The pan-LOX inhibitor NDGA was
an effective inhibitor of RSL3 induced
cell death across all LOX-overproducing cell lines (EC50 = 387–437 nM). Interestingly, it was similarly potent in
the wild-type cells that were devoid of LOX activity. Perhaps more
surprisingly, zileuton, a 5-LOX-selective inhibitor, was not only
a moderately potent inhibitor of ferroptosis in 5-LOX overproducing
cells (EC50 = 1.6 μM), but it was similarly potent
in the nontransfected cells as well as in cells transfected to overproduce
p12-LOX and 15-LOX-1. Investigations with PD146176, a 15-LOX-1 selective
inhibitor, produced similar results, in that the compound was equally
potent in all cell lines. In contrast, 5-LOX inhibitors CAY10649 and
CJ-13610[31,32] were ineffective inhibitors of ferroptosis
in all cell lines.[33] From these results,
it is clear that LOX inhibitory activity is not at all correlated
with antiferroptotic potency.Lip-1 and Fer-1, the archetypal
ferroptosis inhibitors, rescued
the transfected cells from RSL3-induced ferroptosis with very similar
potencies to those determined in the wild-type cells. For example,
in the wild-type cells the EC50 for Lip-1 was 8.9 nM, while
it was 12, 20, and 15 nM for the 5-LOX, p12-LOX, and 15-LOX-1 overproducing
cells, respectively. Similar results were obtained with Fer-1. Recent
results from our group have demonstrated that both Lip-1 and Fer-1
inhibit ferroptosis via their RTA activity, which is excellent in
lipid bilayers.[20] Consistent with the foregoing
results, α-tocopherol (α-TOH) and the improved aza-tocopherol
analogue (C15-THN) were also similarly potent in each of
the cell lines.It should be noted that these results are inconsistent
with the
suggestion that the antiferroptotic activity of α-TOH is due
to its ability to inhibit 15-LOX-1 (by inserting its lipophilic side
chain into the active site and precluding access of the substrate).[15] To provide further insight on this point, 2,2,7,8-pentamethyl-6-chromanol
(PMC, Figure D), a
truncated analogue of α-TOH lacking the lipophilic side chain,
was also assayed and was shown to be an excellent inhibitor of ferroptosis
in all cell lines, suggesting that the lipophilic side chain of α-TOH
is not only unnecessary for its inhibitory activity, but also reduces
its potency (e.g., EC50 = 59 nM in the nontransfected cells
compared to 4.8 μM for α-TOH). These results are fully
consistent with the greater RTA activity of PMC compared to α-TOH
in lipid bilayers, which can be ascribed to improved dynamics.[34] Furthermore, we found that O-methylated α-TOH (α-TOMe) was not only devoid of LOX
inhibitory activity (Figure S3C), but was
unable to rescue any of the cells from ferroptosis at concentrations
up to 10 μM (Figure S3D). These results
are consistent with a previous report wherein it was shown that α-TOH
does not inhibit 15-LOX-1 at concentrations where it is effective
at subverting ferroptosis.[20]
Cytoprotective
LOX Inhibitors Are Also Good RTAs
The
ability of isoform-selective LOX inhibitors to inhibit ferroptosis
in all cell lines with similar potency led us to speculate whether
these compounds have off-target effects that underlie their cytoprotective
properties. In particular, we wondered if the cytoprotective LOX inhibitors
were RTAs, while those LOX inhibitors devoid of antiferroptotic activity
were not RTAs. Thus, we determined the RTA activity of NDGA, zileuton,
PD146176, CAY10649, and CJ-13610 in inhibited autoxidations of cumene,[35] as well as in egg phosphatidylcholine unilammelar
liposomes.[20,24] Reaction progress was monitored
by the consumption of STY-BODIPY, a highly absorbing autoxidizable
cosubstrate (Figure A). The rate constant for peroxyl radical-trapping (or the inhibition
rate constant, kinh) was determined from
the initial (inhibited) rate of dye consumption as in eq 1, whereas
the reaction stoichiometry (how many peroxyl radicals are trapped
by each molecule of RTA) is given from the length of the inhibited
period as in eq 2. The autoxidation traces are shown in Figures B and 3C, with the kinetic data tabulated below them.
Figure 3
STY-BODIPY (A) serves
as the signal carrier in inhibited autoxidations,
enabling determination of inhibition rate constants (kinh) and stoichiometries (n) for reactions
of inhibitors with chain-carrying peroxyl radicals (eqs 1 and 2, respectively).
Coautoxidations of cumene (3.6 M) and STY-BODIPY (10 μM) initiated
by AIBN (6 mM) in chlorobenzene at 37 °C (black) and inhibited
by 2 μM of NDGA, zileuton, PD146176, CAY10649, CJ-13610, Lip-1,
Fer-1, C15-THN, α-TOH, and PMC (B). Coautoxidations
of egg phosphatidylcholine liposomes (1.0 mM) and STY-BODIPY (10 μM)
suspended in phosphate-buffered saline (10 mM) at pH 7.4 initiated
by MeOAMVN (0.2 mM) at 37 °C (black) and inhibited by 2 μM
of NDGA, zileuton, PD146176, CAY10649, CJ-13610, Lip-1, Fer-1, C15-THN, α-TOH, and PMC (C). Inhibition rate constants
obtained from coautoxidations of cumene (D) or phosphatidylcholine
liposomes (E) with STY-BODIPY at 37 °C. *Rate constants were
determined from styrene/PBD-BODIPY co-autoxidations, see ref. (20).
STY-BODIPY (A) serves
as the signal carrier in inhibited autoxidations,
enabling determination of inhibition rate constants (kinh) and stoichiometries (n) for reactions
of inhibitors with chain-carrying peroxyl radicals (eqs 1 and 2, respectively).
Coautoxidations of cumene (3.6 M) and STY-BODIPY (10 μM) initiated
by AIBN (6 mM) in chlorobenzene at 37 °C (black) and inhibited
by 2 μM of NDGA, zileuton, PD146176, CAY10649, CJ-13610, Lip-1,
Fer-1, C15-THN, α-TOH, and PMC (B). Coautoxidations
of egg phosphatidylcholine liposomes (1.0 mM) and STY-BODIPY (10 μM)
suspended in phosphate-buffered saline (10 mM) at pH 7.4 initiated
by MeOAMVN (0.2 mM) at 37 °C (black) and inhibited by 2 μM
of NDGA, zileuton, PD146176, CAY10649, CJ-13610, Lip-1, Fer-1, C15-THN, α-TOH, and PMC (C). Inhibition rate constants
obtained from coautoxidations of cumene (D) or phosphatidylcholine
liposomes (E) with STY-BODIPY at 37 °C. *Rate constants were
determined from styrene/PBD-BODIPY co-autoxidations, see ref. (20).The results for the known RTAs are fully consistent with
previous
reports. They are good to excellent inhibitors of cumene autoxidation
(Figure B, Figure S3A), with kinh varying from as low as 2.4 × 105 M–1 s–1 for Lip-1 to as high as 8.8 × 107 M–1 s–1 for C15-THN. The cytoprotective LOX inhibitors NDGA, zileuton, and PD146176
clearly display reactivity as RTAs, ranging from moderately reactive
(PD146176, kinh = 6.3 × 104 M–1 s–1) to highly reactive
(kinh = 1.7 × 106 and
1.2 × 106 M–1 s–1 for NDGA and zileuton, respectively). On the other hand, the LOX
inhibitors which were devoid of antiferroptotic activity were unable
to inhibit the autoxidation of cumene. The reactivity of NDGA, zileuton,
and PD146176 is explained by the presence of labile phenolic O–H
bonds in NDGA,[36] the hydroxamic acid O–H
bond in zileuton,[37] and arylamine N–H
bond in PD146176. In contrast, CAY10649 and CJ-13610 do not possess
labile H-atoms that could reduce autoxidation chain-carrying peroxyl
radicals.Similar results were obtained in the more biologically
relevant
model system of egg phosphatidylcholine liposomes (Figure C, Figure S3A), albeit where the differences in RTA activity between
the compounds were suppressed due to limited diffusion and H-bonding
interactions.[34,38] All cytoprotective compounds
had apparent kinh ranging from 4.7 ×
103 M–1 s–1 to 9.3
× 104 M–1 s–1.
Again, α-TOMe (Figure S3E,F) and
the LOX inhibitors which were devoid of antiferroptotic activity (CAY10649
and CJ-13610) were unreactive.
Only Arachidonic Acid Deuterated
at All Bis-Allylic Positions
Protects Cells from Ferroptosis
It was recently shown that
cells grown in media supplemented with 11,11-d2-linoleic acid (d2-LA) are refractory
to ferroptosis induced with either erastin or RSL3.[16] Following on this observation, if LOX-catalyzed oxidation
of AA—its native substrate—plays a key role in ferroptosis
execution, cells grown in media supplemented with AA labeled at the
bis-allylic positions from which each LOX isoform regiospecifically
abstracts a H-atom should be protected from ferroptosis. The use of
regiospecifically labeled substrates[39] as
isoform-selective inhibitors of LOX (Figure A, Figure S4A,B) removes any uncertainty regarding off-target effects of inhibitors
or interactions of inhibitors with the agents used to induce ferroptosis.
As expected, 7,7-d2-AA inhibited 5-LOX
activity, but not p12-LOX or 15-LOX-1 activity (Figure B), 10,10-d2-AA
inhibited p12-LOX activity, but not 5-LOX or 15-LOX-1 activity (Figure C), and 13,13-d2-AA inhibited 15-LOX-1 activity, but not 5-LOX
or p12-LOX activity (Figure D). These results are consistent with the very large kinetic isotope effects reported for LOX-catalyzed oxidation
of AA by p12-LOX and 15-LOX-1.[40]
Figure 4
(A) Structures
of deuterated arachidonic acids. HPETE formation
in cells overexpressing 5-LOX (B), p12-LOX (C), and 15-LOX-1 (D) incubated
with 70 μM AA (black), 7,7,10,10,13,13-d6-AA (red), 7,7-d2-AA (blue), 10,10-d2-AA (green), and 13,13-d2-AA (magenta). RSL3-induced ferroptosis in nontransfected
HEK293 cells (E) and transfected cells overexpressing 5-LOX (F), p12-LOX
(G), and 15-LOX-1 (H) preincubated with 40 μM arachidonic acid
(black, ●), 7,7-d2-AA (blue, ▲),
10,10-d2-AA (green, ◆), 13,13-d2-AA (magenta, ▼), and 7,7,10,10,13,13-d6-AA (red, ■).
(A) Structures
of deuterated arachidonic acids. HPETE formation
in cells overexpressing 5-LOX (B), p12-LOX (C), and 15-LOX-1 (D) incubated
with 70 μM AA (black), 7,7,10,10,13,13-d6-AA (red), 7,7-d2-AA (blue), 10,10-d2-AA (green), and 13,13-d2-AA (magenta). RSL3-induced ferroptosis in nontransfected
HEK293 cells (E) and transfected cells overexpressing 5-LOX (F), p12-LOX
(G), and 15-LOX-1 (H) preincubated with 40 μM arachidonic acid
(black, ●), 7,7-d2-AA (blue, ▲),
10,10-d2-AA (green, ◆), 13,13-d2-AA (magenta, ▼), and 7,7,10,10,13,13-d6-AA (red, ■).Despite their ability to specifically inhibit a given LOX
isoform,
the addition of the d2-AAs had no significant
cytoprotective effect on the corresponding LOX-overexpressing cells
(Figures E–H).
However, consistent with the observation that the addition of d2-LA is cytoprotective against ferroptosis,
a d6-AA where all abstractable (bis-allylic)
H-atoms were replaced with deuterium atoms was strongly cytoprotective.
This observation is consistent with the large kinetic isotope effects
reported for hydrocarbon autoxidation,[41] and specifically H-atom transfer from polyunsaturated lipids.[42]
Induction of Ferroptosis Does Not Require
Specific Hydroperoxide(s)
Given the foregoing, we wondered
if the H(P)ETEs produced by LOX
activity simply contribute to the cellular pool of LOOH to accelerate
initiation of massive (nonspecific) autoxidation that drives cell
death. Interestingly, when the concentrations of 5-, 12-, and 15-H(P)ETE
were monitored in the four cell lines postinduction with RSL3 (Figure A–D), the
concentration of total LOOH peaked at ca. 20 μM, suggesting
that, once a critical threshold of LOOH is achieved, ferroptosis is
triggered. To corroborate that the overall concentration of hydroperoxide
is far more relevant than its structure, we investigated if cells
were similarly sensitized to RSL3 induced ferroptosis upon addition
of exogenous LOOH. Four compounds that would not be formed endogenously
by LOX catalysis were investigated: 10-hydroperoxy oleic acid (oleic
10-OOH), phosphatidylcholine esterified 10-hydroperoxyoleate (PC-oleate-10-OOH),
cholesterol-7-hydroperoxide, and a generic abiotic lipophilic hydroperoxide
(tert-dodecyl-OOH). The data in Figure F show that the exogenous LOOH
sensitize the cells to RSL3 induced ferroptosis to a similar extent.
Moreover, the concentration of added LOOH necessary to achieve cell
death is strikingly similar to the amount of HPETE produced endogenously
in the LOX-overexpressing cells that is associated with cell death.
A similar lack of structural dependence on the ability of hydroperoxides
to sensitize cells to RSL3-induced cell death was also observed in
Pfa1 mouse embryonic fibroblasts (MEFs). These cells have been studied
extensively and have been reported to be highly sensitive to ferroptosis.[6,17] Similar to HEK293 cells, the MEFs do not express detectable amounts
of 5-LOX, p12-LOX, or 15-LOX-1 (Figure S5A–C) and, consistent with their greater sensitivity to ferroptosis (compare
LD50s of 38 and 113 nM for RSL3 and erastin, respectively,
to 6.8 and 6.6 μM in HEK293 cells, Figure S5D), lower concentrations of added hydroperoxide sensitized
them to cell death (Figure S5F).
Figure 5
Formation of
5-HETE (blue, ●), 12-HETE (red, ■),
and 15-HETE (green, ▲) in nontransfected HEK293 cells (A),
and cells overexpressing 5-LOX (B), p12-LOX (C), and 15-LOX-1 (D)
treated with 5 μM RSL3 and 40 μM arachidonic acid. Cell
viability is overlaid on each graph (red ×). (E) Sensitization
of wild-type cells to ferroptosis with 0.5 μM RSL3 in the presence
of various concentrations of exogenously prepared hydroperoxides:
oleic 10-OOH (green), cholesterol-7-OOH (red), tert-dodecyl-OOH (blue), or PC-oleate 10-OOH (black). (F) Viability of
HEK293 cells exposed to oleic-10-OOH in the presence of 0.5 μM
RSL3 (black, ●) inhibited with 3.1 (red, ■), 6.3 (blue,
▲), 12.5 (green, ◆), 25 (magenta, ●), 50 (cyan,
▼), or 100 (yellow, ★) nM Lip-1.
Formation of
5-HETE (blue, ●), 12-HETE (red, ■),
and 15-HETE (green, ▲) in nontransfected HEK293 cells (A),
and cells overexpressing 5-LOX (B), p12-LOX (C), and 15-LOX-1 (D)
treated with 5 μM RSL3 and 40 μM arachidonic acid. Cell
viability is overlaid on each graph (red ×). (E) Sensitization
of wild-type cells to ferroptosis with 0.5 μM RSL3 in the presence
of various concentrations of exogenously prepared hydroperoxides:
oleic 10-OOH (green), cholesterol-7-OOH (red), tert-dodecyl-OOH (blue), or PC-oleate 10-OOH (black). (F) Viability of
HEK293 cells exposed to oleic-10-OOH in the presence of 0.5 μM
RSL3 (black, ●) inhibited with 3.1 (red, ■), 6.3 (blue,
▲), 12.5 (green, ◆), 25 (magenta, ●), 50 (cyan,
▼), or 100 (yellow, ★) nM Lip-1.If LOX catalysis serves simply to supply hydroperoxides to
initiate
massive autoxidation that drives ferroptosis execution, it follows
that as long as there is a sufficiently high concentration of RTA
to limit the propagation of autoxidation, higher concentrations of
LOOH—endogenous or exogenous—will be tolerated by the
cell. This appears to be the case, an example of which is shown in Figure F wherein the concentration
of oleic hydroperoxide added to wild-type cells was increased in the
presence of increasing amounts of Lip-1. While the entire cell population
is dead upon incubation with 25 μM oleic 10-OOH, cell viability
was increased in a dose-dependent manner with added Lip-1, with full
viability being restored at 100 nM Lip-1. It is important to note
that Lip-1 does not react directly with oleic 10-OOH under these conditions
(Figure S3G).
Discussion
Polyunsaturated
fatty acids are integral structural components
of biological membranes and serve as precursors to a diverse array
of signaling molecules that are essential to maintaining cellular
and tissue homeostasis as well as the control of cell proliferation
and differentiation. The unsaturation that imparts the molecular geometry
necessary to contribute to both a dynamic lipid bilayer and structural
diversity of signaling molecules makes PUFAs particularly sensitive
to the same deleterious reactions responsible for the degradation
of all hydrocarbon-derived products: autoxidation. Autoxidation is
the free radical chain reaction that formally inserts a molecule of
oxygen into the C–H bond of an organic substrate to yield a
hydroperoxide. The hydroperoxide can undergo several possible reactions,
including dehydration to yield a carbonyl compound or acid-catalyzed
Hock fragmentation to yield a pair of carbonyl compounds (or their
equivalent).[43,44] In a biological context, lipid-derived
carbonyls have long been directly implicated in cell death through
caspase-dependent apoptotic processes,[45] but only recently have lipid hydroperoxides themselves been implicated
directly in regulated cell death, via ferroptosis.[2]Lipoxygenase-catalyzed oxidation of PUFAs—primarily
arachidonic
acid—have been proposed to steer cells toward ferroptosis.[15,16] However, the foregoing results clearly demonstrate that although
LOX-catalyzed oxygenation of AA may sensitize cells to ferroptosis
(induced by the most commonly employed agents RSL3 and erastin),[33]it is not strictly required. Accordingly, although the inhibition of LOX catalysis cannot rescue
cells from ferroptosis induced by the most common ferroptosis-inducing
agents, radical-trapping antioxidants can, implying a central role
for autoxidation in the execution of ferroptosis.The well-established
kinetics of hydrocarbon autoxidation[46,47] enable the
rationalization of many observations associated with
the mechanism of ferroptosis. The expression that generally describes
these kinetics—which was first derived from experiments in
homogeneous organic solution, but which has also been shown to apply
in lipid bilayers[48]—is shown in
eq 3 in Figure A.
It indicates that the rate of hydroperoxide formation is proportional
to the concentration of the substrate (L–H), the rate constant
for H-atom abstraction from the substrate by a chain-carrying peroxyl
radical (kp), the rate of initiation (Ri), and the rate constant for termination of
the chain reaction by the reaction of two chain-carrying peroxyl radicals
(kt). Since autoxidation is, in a sense,
auto-catalytic, i.e. the reaction product can initiate new chain reactions
(Figure B), the rate
of initiation (Ri) isn't constant,
but
increases with the conversion of lipids to their corresponding hydroperoxides.
Thus, any process that contributes to the cellular pool of LOOH—such
as LOX catalysis—will increase Ri and therefore the overall rate, sensitizing cells to ferroptosis.
In contrast, gene products that decrease the overall pool of LOOH,
such as Gpx4, will decrease Ri and suppress
ferroptosis. Moreover, any process that increases the pool of autoxidizable
lipid (i.e., [LH]), such as acyl-CoA synthetase long chain family
member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3),
will increase the overall rate and sensitize cells to ferroptosis
activity. In contrast, supplementing cells with less autoxidizable
lipids (e.g., D-PUFAs) or with inhibitors of ACSL4 or LPCAT3,[12] will suppress ferroptosis.
Figure 6
Kinetic expressions for
uninhibited and inhibited lipid autoxidation
(A). Schematic demonstrating the interplay between small molecule
and enzymatic inducers and inhibitors of ferroptotic cell death associated
with the accumulation of (phospho)lipid hydroperoxides (B).
Kinetic expressions for
uninhibited and inhibited lipid autoxidation
(A). Schematic demonstrating the interplay between small molecule
and enzymatic inducers and inhibitors of ferroptotic cell death associated
with the accumulation of (phospho)lipid hydroperoxides (B).In homogeneous solution and lipid
bilayers, the kinetics of the
inhibited autoxidation of hydrocarbons is generally described by eq
4 in Figure A.[47,48] Thus, compounds with a sufficiently high rate constant (kinh) or stoichiometry (n) for
reactions with peroxyl radicals (that do not generate a chain-initiating
or chain-propagating radical) will inhibit autocatalytic LOOH formation.
These RTA compounds can be either highly reactive or have a high radical-trapping
capacity or, ideally, both. α-TOH, Nature’s major lipophilic
RTA,[22] is only moderately reactive in lipid
bilayers,[34,48] but its radical-trapping capacity can be
bolstered by its regeneration by coantioxidants, such as ascorbate
and reduced co-Q10.[49,50] The aza-TOH analogue,
C15-THN, is much more reactive in lipid bilayers and is
also regenerable by coantioxidants,[23] which
translates to high potency in cells. Lip-1 and Fer-1 also have good
activity in lipid bilayers. It remains unclear whether these compounds
are regenerable, but it would seem that they have higher radical-trapping
capacity in lipid bilayers than either α-TOH or C15-THN, possibly due to the formation of nitroxides,[20] which can act as catalytic RTAs.[51] The LOX inhibitors NDGA, zileuton, and PD146176 also clearly display
this activity, explaining why they inhibit ferroptosis in all four
cell lines with similar potencies. Most importantly, LOX inhibitors
devoid of any RTA activity (CAY10649 and CJ-13610) do not. It should
be noted that other LOX inhibitors have been reported to inhibit ferroptosis,
specifically, baicalein,[16,52,53] CDC,[16] and AA-861.[16,52] We have confirmed that these compounds also have significant RTA
activity (see Figure S6A–D), which
can be ascribed to the labile H-atoms found on their respective redox-active
functionalities: CDC contains a lipophilic catechol, baicalein a lipophilic
pyrogallol, and AA-861 is a lipophilic quinone analogous to coenzyme
Q10 that can be reduced in situ to yield a hydroquinone.[25] These results serve to caution investigators
to avoid making conclusions regarding the involvement of LOX-catalyzed
lipid oxidation in cell death on the basis of inhibition by (redox-active)
LOX inhibitors, including (but not limited to) NDGA,[53−55] zileuton,[16,56,57] PD146176,[10,15,16,55,58,59] bacalein,[16,52,53,59] CDC[16] and AA-861.[16]Since hydrocarbon
autoxidation can be autocatalytic, the rate of
initiation (Ri) is not constant, but ever-increasing,
depending on the LOOH concentration and the availability of low valent
metals (e.g., Fe2+) and/or other one-electron-reducing
agents capable of converting hydroperoxides to chain-initiating species
(i.e., hydroxyl and/or alkoxyl radicals). As Ri increases, the cell’s intrinsic RTA defenses are rapidly
depleted and, with the accumulation of LOOH left unabated, cell death
is inevitable. In HEK293 cells (transfected to overexpress LOX or
not) the LOOH concentration at which this takes place appears to be
ca. 20 μM. This “threshold” is likely to vary
with cell type, metabolic state, and/or specific culture conditions
that can affect either Ri or the intrinsic
RTA complement/activity of the cell. Indeed, we have shown that cells
that are more sensitive to ferroptosis, such as the well-studied mouse
embryonic fibroblasts,[17] are characterized
by a significantly lower threshold, and supplementing cells with additional
RTA can significantly raise this threshold.[60]Although the results presented above establish autoxidation
as
the central process in the execution stage of ferroptosis, it must
be stressed that the events leading up to it—events that enable
the initial buildup of LOOH to a level where Ri will overwhelm a cell’s limited intrinsic RTA capacity—remain
unclear. It is at this initiation stage that LOXs may play a role,
and their expression levels—as well as those of proteins/enzymes
that may be associated with their activity (e.g., PEBP1, a scaffolding
protein that was recently reported to assist 15-LOX-1 in acquiring
phosphatidylethanolamine-esterified AA for oxygenation,[61]Figure S7)—may
contribute to the sensitivity of a given cell type to ferroptosis.
It is also at this stage where pharmacological intervention to suppress
lipid oxidation with LOX inhibitors or deuteratedPUFAs[62] may be useful in pathological contexts. Consistent
with this view, 5-LOX-overexpressing cells passaged in the presence
of CJ-13610 (the non-redox-active 5-LOX selective inhibitor) were
desensitized to RSL3-induced ferroptosis, while the p12-LOX- and 15-LOX-1-overexpressing
cells remained sensitized (Figure S4C,D). Although RTA treatment is clearly effective in subverting ferroptosis
in cell culture, it targets the downstream process (autoxidation),
and once the RTA is exhausted, if the underlying condition remains
(e.g., ineffective Gpx4 and/or GSHinsufficiency), the cells will
die. Indeed, Gpx4–/– cells were viable in
α-TOH-enriched media (passaged 20 times), but underwent cell
death within 24 h in its absence.[12]In vivo, where accumulation of initiating LOOH may be slower,
and induction of ferroptosis correspondingly less acute, LOX inhibition
may ultimately prove effective.
Authors: Valerian E Kagan; Gaowei Mao; Feng Qu; Jose Pedro Friedmann Angeli; Sebastian Doll; Claudette St Croix; Haider Hussain Dar; Bing Liu; Vladimir A Tyurin; Vladimir B Ritov; Alexandr A Kapralov; Andrew A Amoscato; Jianfei Jiang; Tamil Anthonymuthu; Dariush Mohammadyani; Qin Yang; Bettina Proneth; Judith Klein-Seetharaman; Simon Watkins; Ivet Bahar; Joel Greenberger; Rama K Mallampalli; Brent R Stockwell; Yulia Y Tyurina; Marcus Conrad; Hülya Bayır Journal: Nat Chem Biol Date: 2016-11-14 Impact factor: 15.040
Authors: Bo Li; Jitendra R Harjani; Nicholas S Cormier; Hasam Madarati; Jeffrey Atkinson; Gonzalo Cosa; Derek A Pratt Journal: J Am Chem Soc Date: 2013-01-18 Impact factor: 15.419
Authors: Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell Journal: Cell Date: 2012-05-25 Impact factor: 41.582
Authors: Wan Seok Yang; Katherine J Kim; Michael M Gaschler; Milesh Patel; Mikhail S Shchepinov; Brent R Stockwell Journal: Proc Natl Acad Sci U S A Date: 2016-08-09 Impact factor: 11.205
Authors: Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell Journal: Nat Rev Drug Discov Date: 2016-01-18 Impact factor: 84.694
Authors: Nicholas Yagoda; Moritz von Rechenberg; Elma Zaganjor; Andras J Bauer; Wan Seok Yang; Daniel J Fridman; Adam J Wolpaw; Inese Smukste; John M Peltier; J Jay Boniface; Richard Smith; Stephen L Lessnick; Sudhir Sahasrabudhe; Brent R Stockwell Journal: Nature Date: 2007-06-14 Impact factor: 49.962
Authors: M A Artyukhova; Y Y Tyurina; C T Chu; T M Zharikova; H Bayır; V E Kagan; P S Timashev Journal: Free Radic Biol Med Date: 2019-06-12 Impact factor: 7.376
Authors: Ofer Beharier; Vladimir A Tyurin; Julie P Goff; Jennifer Guerrero-Santoro; Kazuhiro Kajiwara; Tianjiao Chu; Yulia Y Tyurina; Claudette M St Croix; Callen T Wallace; Samuel Parry; W Tony Parks; Valerian E Kagan; Yoel Sadovsky Journal: Proc Natl Acad Sci U S A Date: 2020-10-21 Impact factor: 11.205